London-based Bioniq, a company specializing in personalized nutritional supplements, has gained another high-profile investor. Manchester United and Portugal national team right-back Diogo Dalot has invested over €1 million in the company, following in the footsteps of global football icon Cristiano Ronaldo, who became a major backer in 2024. With this latest investment, Bioniq continues to strengthen its position in the fast-growing market of AI-driven, science-backed health optimization.
Diogo Dalot is not just an investor but also a long-time Bioniq user. Having integrated the brand’s tailored supplements into his routine for over four years, he brings firsthand experience of its impact on performance and recovery. Vadim Fedotov, Founder and CEO of Bioniq, highlighted Dalot’s dedication to performance enhancement and his alignment with the company’s vision, emphasizing that his investment further validates the shift toward precision-based health solutions.
Bioniq was founded in 2019 by Vadim Fedotov, a former German national basketball player, and health entrepreneur James Hardy. The company has built one of the most extensive proprietary biochemical databases, leveraging AI-powered analysis of blood biomarker data to create hyper-personalized supplement formulas. Operating in over 70 countries, Bioniq has crafted individualized supplement plans for more than 300,000 users, from elite athletes to professionals seeking optimal health.
Unlike generic supplement brands, Bioniq focuses on precision and scientific validation. Each formula is based on a customer’s unique blood test results, ensuring that nutrient deficiencies are addressed with targeted solutions. The company continuously refines its recommendations using AI-driven insights, providing customers with before-and-after snapshots of their progress. This data-driven approach has attracted a growing base of elite athletes, including football World Cup champions, NBA All-Stars, and Iron Man winners.
Dalot’s involvement extends beyond financial investment, as he actively collaborates with Bioniq on product innovation. The introduction of Bioniq’s Build Your Own supplement line has allowed him to fine-tune his nutrition based on specific training and performance goals. While the PRO formula is designed to reduce inflammation, improve resilience, and enhance endurance, the Build Your Own option enables him to adjust nutrient intake to support recovery and muscle-building processes. Dalot credits Bioniq with helping him unlock new levels of performance, stating that having a supplement tailored specifically to his body has made a measurable difference in his career.
The global supplements market is experiencing a shift toward personalized health solutions, with increasing consumer demand for science-backed nutrition. According to Bioniq, the industry was valued at €162 billion in 2023 and is expected to grow at a CAGR of 9.1% through 2030. This trend has also attracted significant investment, with Bioniq’s 2024 Series B funding round securing €13.7 million from leading European venture capital firms.
Bioniq’s credibility in the performance nutrition space has been further reinforced by partnerships with premier health and sports institutions, including Lanserhof and UFC. The company’s ability to provide quantifiable, science-backed results has positioned it as a leading player in the evolving landscape of personalized health solutions. With Dalot’s investment and continued athlete-driven innovation, Bioniq is poised for even greater global expansion, catering to the rising demand for customized supplements that enhance both physical and cognitive performance.
